Last checked at 3 May 2016 07:01
ASTRAZENECA COMPLETES DIVESTMENT OF IMDUR
TO CHINA MEDICAL SYSTEM HOLDINGS
AstraZeneca today announced that it has completed the divestment of the global rights to Imdur, outside the US, to China Medical System Holdings Ltd and its associated company, Tibet Rhodiola Pharmaceutical Holding Co. Under the agreement, AstraZeneca will receive $190 million for the rights to Imdur.
Imdur is a mature medicine for the prevention of angina in patients with heart disease and achieved global sales outside the US of $57 million in 2015. Income from the agreement will be reported as Core Other Operating Income.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology - as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
CONTACTS
Media Enquiries
|
| |
Neil Burrows | UK/Global | +44 20 7604 8032 |
Vanessa Rhodes
| UK/Global | +44 20 7604 8037 |
Karen Birmingham | UK/Global | +44 20 7604 8120 |
Jacob Lund
| Sweden | +46 8 553 260 20 |
Michele Meixell | US | +1 302 885 2677 |
Investor Enquiries | ||
UK | ||
Thomas Kudsk Larsen
| +44 7818 524185 | |
Eugenia Litz | RIA
| +44 7884 735627 |
Nick Stone | CVMD
| +44 7717 618834 |
Craig Marks | Finance | +44 7881 615764 |
Christer Gruvris
| Consensus Forecasts | +44 7827 836825 |
US | ||
Lindsey Trickett | Oncology, ING | +1 240 543 7970 |
Mitch Chan | Oncology | +1 240 477 3771 |
Dial / Toll-Free | +1 866 381 7277 |
Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease,
ING - Infection, Neuroscience and Gastrointestinal
03 May 2016
-ENDS-